JAPAN'S JANSSEN KK OFFERS INJECTABLE BIWEEKLY SCHIZOPHRENIA DRUG

Thu. June 11, 2009; Posted: 11:37 PM

TOKYO, Jun 12, 2009 (AsiaPulse via COMTEX) -- JNJ | Quote | Chart | News | PowerRating -- Japan's Janssen Pharmaceutical KK, part of the U.S.-based Johnson & Johnson group, will begin marketing an injectable version of the schizophrenia drug Risperdal as early as June.

By offering Risperdal in a more convenient biweekly injectable form as opposed to a daily oral preparation, the company aims to fend off competition from generic versions.

Risperdal is Janssen Pharmaceutical's leading product, accounting for some 30 per cent of the company's total sales in 2008. But sales in 2008 totaled only 29.5 billion yen (US$302 million), compared with the 34.5 billion yen in 2007, because the product had to vie with generic versions.

Janssen already sells Risperdal in the form of pills, granules, liquid and quick-dissolving tablets. But these need to be taken twice a day, so people suffering from schizophrenia have difficulty staying on their medication.

The new injectable form of Risperdal, to be sold as Risperdal Consta, is formulated in tiny beads of a slow-release polymer that is injected into the muscle, where it gradually dissolves over the course of two weeks.

Risperdal Consta is already being sold overseas. But for the Japanese market, Janssen Pharmaceutical halved the size of the packaging so the product takes up less room in the small refrigerators found in Japanese hospitals. The company obtained approval to market the formulation from the Health Ministry in April.

(Nikkei)

For full details on Johnson & Johnson (JNJ) click here. Johnson & Johnson (JNJ) has Short Term PowerRatings of 5. Details on Johnson & Johnson (JNJ) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

Tax Relief Bank Levy Wage Garnishment

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.